Stock DCPH DECIPHERA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
14.65 USD +3.31% Intraday chart for Deciphera Pharmaceuticals, Inc. -0.14% -9.18%
01:18pm Japan's Ono Pharmaceutical to buy Deciphera for $2.4 billion RE
13/03 Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Japan's Ono Pharmaceutical to buy Deciphera for $2.4 billion
RE
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
PR
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
BU
Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises
MT
Transcript : Deciphera Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 06, 2024
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M
MT
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
BU
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Rate Doubts Keep -2-
DJ
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
BU
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
BU
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib
MT
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
BU
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries
MT
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe
CI
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DCPH Stock
  4. News Deciphera Pharmaceuticals, Inc.